首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor.
【2h】

Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor.

机译:Asn-293参与立体定向激动剂识别和β2肾上腺素受体的激活。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To investigate the molecular mechanism for stereospecific binding of agonists to beta 2-adrenergic receptors we used receptor models to identify potential binding sites for the beta-OH-group of the ligand, which defines the chiral center. Ser-165, located in transmembrane helix IV, and Asn-293, situated in the upper half of transmembrane helix VI, were identified as potential binding sites. Mutation of Ser-165 to Ala did not change the binding of either isoproterenol isomer as revealed after transient expression in human embryonic kidney (HEK)-293 cells. In contrast, a receptor mutant in which Asn-293 was replaced by Leu showed substantial loss of stereospecific isoproterenol binding. Adenylyl cyclase stimulation by this mutant after stable expression in CHO cells confirmed the substantial loss of stereospecificity for isoproterenol. In a series of agonists the loss of affinity in the Leu-293 mutant receptor was strongly correlated with the intrinsic activity of the compounds. Full agonists showed a 10-30-fold affinity loss, whereas partial agonists had almost the same affinity for both receptors. Stereospecific recognition of antagonists was unaltered in the Leu-293 mutant receptor. These data indicate a relationship between stereospecificity and intrinsic activity of agonists and suggest that Asn-293 is important for both properties of the agonist-receptor interaction.
机译:为了研究激动剂与β2-肾上腺素受体立体定向结合的分子机制,我们使用受体模型来识别配体的β-OH-基团(定义了手性中心)的潜在结合位点。位于跨膜螺旋IV的Ser-165和位于跨膜螺旋VI上半部分的Asn-293被确定为潜在的结合位点。在人类胚胎肾脏(HEK)-293细胞中瞬时表达后,Ser-165突变为Ala并没有改变异丙肾上腺素异构体的结合。相反,其中Asn-293被Leu取代的受体突变体显示立体特异性异丙肾上腺素结合的实质性丧失。在CHO细胞中稳定表达后,该突变体对腺苷酸环化酶的刺激作用证实了异丙肾上腺素立体特异性的实质性丧失。在一系列激动剂中,Leu-293突变受体中亲和力的丧失与化合物的内在活性密切相关。完全激动剂显示出10-30倍的亲和力损失,而部分激动剂对两种受体的亲和力几乎相同。拮抗剂的立体特异性识别在Leu-293突变体受体中没有改变。这些数据表明了激动剂的立体特异性和内在活性之间的关系,并表明Asn-293对于激动剂-受体相互作用的两个性质都是重要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号